MedKoo Cat#: 412348 | Name: Quinidine polygalacturonate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Quinidine polygalacturonate is used to treat or prevent many types of irregular heartbeats (heart arrhythmias such as atrial fibrillation). Quinidine can greatly improve your ability to perform normal activities by decreasing the number of irregular heartbeats you have.

Chemical Structure

Quinidine polygalacturonate
Quinidine polygalacturonate
CAS#27555-34-6 (polygalacturonate)

Theoretical Analysis

MedKoo Cat#: 412348

Name: Quinidine polygalacturonate

CAS#: 27555-34-6 (polygalacturonate)

Chemical Formula: C26H32N2O9

Exact Mass: 516.2108

Molecular Weight: 516.55

Elemental Analysis: C, 60.46; H, 6.24; N, 5.42; O, 27.88

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Synonym
Quinidine polygalacturonate; Cardioquin; Naticardina; Ritmocor
IUPAC/Chemical Name
(S)-[(2R,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;(2S,3R,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid
InChi Key
OPDHRDFWNKFWIN-NUKLETMZSA-N
InChi Code
InChI=1S/C26H32N2O9/c1-3-13-12-28-9-7-14(13)10-19(28)26(36,24(33)22(31)20(29)21(30)23(32)25(34)35)17-6-8-27-18-5-4-15(37-2)11-16(17)18/h3-6,8,11,13-14,19-23,29-32,36H,1,7,9-10,12H2,2H3,(H,34,35)/t13-,14-,19+,20?,21?,22?,23?,26-/m0/s1
SMILES Code
O[C@@]([C@@H]1N(CC2)C[C@H](C=C)[C@]2([H])C1)(C(C(O)C(O)C(O)C(O)C(O)=O)=O)C3=CC=NC4=CC=C(OC)C=C34
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 516.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Dahl JR, Ueda CT, Meyers DG, Wulf BG. Comparative bioavailability characteristics of commercial quinidine polygalacturonate and sulfate tablets. DICP. 1990 Jul-Aug;24(7-8):685-8. doi: 10.1177/106002809002400704. PMID: 2375136. 2: Inama G, Durin O, Pedrinazzi C, Berisso MZ, Furlanello F. 'Orphan drugs' in cardiology: nadolol and quinidine. J Cardiovasc Med (Hagerstown). 2010 Feb;11(2):143-4. doi: 10.2459/JCM.0b013e3283313525. PMID: 19829129. 3: GOLDBERG WM, CHAKRABARTI SG. THE RELATIONSHIP OF DOSAGE SCHEDULE TO THE BLOOD LEVEL OF QUINIDINE, USING ALL AVAILABLE QUINIDINE PREPARATIONS. Can Med Assoc J. 1964 Nov 7;91(19):991-6. PMID: 14222674; PMCID: PMC1928075. 4: Frigo GM, Perucca E, Teggia-Droghi M, Gatti G, Mussini A, Salerno J. Comparison of quinidine plasma concentration curves following oral administration of some short- and long-acting formulations. Br J Clin Pharmacol. 1977 Aug;4(4):449-54. doi: 10.1111/j.1365-2125.1977.tb00760.x. PMID: 901736; PMCID: PMC1429058. 5: Soeterboek AM, Van Thiel M, Eng C. Serum quinidine levels after chronic administration of four different quinidine formulations. J Int Med Res. 1976;4(6):393-401. doi: 10.1177/030006057600400604. PMID: 1027633. 6: Normand JP, Legendre M, Kahn JC, Bourdarias JP, Mathivat A. Comparative efficacy of short-acting and long-acting quinidine for maintenance of sinus rhythm after electrical conversion of atrial fibrillation. Br Heart J. 1976 Apr;38(4):381-7. doi: 10.1136/hrt.38.4.381. PMID: 773392; PMCID: PMC483005. 7: FERRARI M, GELATI M, SALVATORE V. [Clinical experience with a new quinidine preparation: quinidine polygalacturonate]. G Clin Med. 1960 Mar;41:309-25. Italian. PMID: 13822401. 8: KHORSANDIAN R, CAPLAN RF, FEINBERG LJ, BELLET S. Plasma quinidine content levels following single oral doses of quinidine polygalacturonate. Am J Med Sci. 1963 Mar;245:311-6. PMID: 14032404. 9: Chimienti M, Regazzi MB, La Rovere MT, Salerno JA, Previtali M, Montericcio V, Rondanelli R, Montemartini C. Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration. Cardiovasc Drugs Ther. 1988 Dec;2(5):679-86. doi: 10.1007/BF00054209. PMID: 2484920. 10: VARELA DE SEIJAS JR, DE RABAGO P, SANCHEZ-CASCOS A, LUIS D. [Conversion of auricular fibrillation to sinusal rhythm with a new quinidine preparation, quinidine polygalacturonate]. Rev Clin Esp. 1962 Feb 28;84:233-40. Spanish. PMID: 13924825.